Over the past decade, Malaysia has gained a reputation as a safe and trusted destination for health care travellers across different backgrounds and all ages.
Malaysia health care has demonstrated unparalleled commitment to improving the health of health care travellers through its world-class quality health care, and easily accessible and comparatively affordable service offerings for the patient’s peace of mind.
Malaysia has grown as an increasingly preferred destination for healthcare travellers seeking fertility, cardiology, oncology, and Hepatitis C related medical treatments, owing to the experienced medical experts, availability of state-of-the-art technology and high-quality treatment options with good clinical outcomes and the overall seamless end-to-end patient experience offered.
Fertility Hub of Asia: Giving Hope to Dreams
As the fertility hub of Asia, Malaysia has been an increasingly preferred health care destination for fertility treatments, experiencing a revenue growth of 67 per cent between 2015 to 2019 from the China market alone, with health care travel contributing a total of 125 per cent year-on-year revenue growth from 2017 to 2018.
With advanced treatments such as AI technology for fertility viability testing being made available, fertility facilities in Malaysia report high success rates such as 82.9% through transfer of a single good graded euploid blastocyst, and 68 per cent in embryo transfers for women above 41 years of age with Preimplantation Genetic Testing (PGT)-source.
Furthermore, out of 30 fertility centres worldwide that have International RTAC accreditation, eight are in Malaysia.
Fertility treatments in Malaysia are also reasonably priced at USD4,000 to USD5,000 per cycle. Patients who seek health care in Malaysia will benefit from a holistic and seamless end-to-end journey experience, where they can expect to receive top-quality care at every phase of their journey, from pre to post treatment.
Cardiology Hub of Asia
Malaysia’s history in cardiology begins in the 1960s, marking the beginning of cardiothoracic surgical services in Malaysia. Soon after, the National Heart Association of Malaysia was established to further expand the country’s expertise on cardiovascular diseases through education, research, and health care policies.
As the 1990s came around, heart care became available at private health care institutions, with the National Heart Institute (IJN) progressing with world-class breakthroughs in heart care. Since its establishment in 1992, IJN has treated over four million patients from various countries around the globe.
With an abundance of world-class hospitals with strong reputations in cardiac care, coupled with the best medical expertise, technologies, and staff, Malaysia is positioned as the cardiology hub of Asia, where health care travellers can access world-class quality heart care at competitive prices.
Malaysia is also home to the first hospital outside of the United States to implant the Micra AV pacemaker, an implantable device for the treatment of a slow heart rate via pacing.
The country is also the first in the Asia-Pacific region to have performed a successful Bio-absorbable Pulmonary Valve (PV) Conduit implant on three children with congenital heart defects (the fifth, sixth and seventh patients in the world to undergo this surgery).
Cancer Care Centre Of Excellence
Apart from being recognised as the cardiology and fertility hubs of Asia, Malaysia is also gaining international reputation as the Cancer Care Centre of Excellence (Cancer COE), emerging as the third most prepared country in the Asia-Pacific region in the fight against cancer, according a study conducted by The Economist‘s Economist Intelligence Unit (EIU).
Malaysia is home to 128 medical and clinical oncologists in both the public and private sectors, who are fully equipped to cater to patient demands.
Out of 79 MHTC member hospitals, more than 30 hospitals focus on multiple types of cancer, including breast, lung, nasopharyngeal, colorectal, and lymphoma.
Furthermore, cancer treatments in Malaysia also heavily focus on palliative care for end-stage cancer, and rehabilitation for cancer survivors. It has access to the latest medical drugs that are not readily available in other parts of Southeast Asia, while keeping the cost of the treatments affordable.
Hepatitis C Treatment Hub Of Asia
In response to the World Health Organization’s (WHO) mission to reduce new viral hepatitis infections by 90 per cent by 2030, Malaysia is paving the way as the Hepatitis C treatment hub of Asia, providing accessible, affordable, and efficacious treatment options.
Hepatitis C is known as a silent disease, and has affected around 58 million people globally. Many are oblivious of this condition, its symptoms, and lack of access to getting the necessary treatment solutions.
If left untreated, Hepatitis C can lead to chronic diseases such as liver cirrhosis and liver cancer. As such, it is important to test, treat and cure by taking preventive care through premium health care screenings.
Malaysia opened its borders on April 1, 2022, and we are looking forward to the day when borders around the world will also be fully reopened.
The country is ready to welcome health care travellers seeking medical care at a safe and trusted destination. Click here for more information.
Mohd Daud Mohd Arif is the CEO of the Malaysia Healthcare Travel Council (MHTC).
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
